Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: Inhibitory effect on cytotoxicity

European Journal of Cancer

Volumn 34, Issue 3, 1998, Pages 394-398

  Sanchez Rovira P ^a   Jimenez, E ^a   Carracedo, J ^a   Barneto, I C ^a   Ramirez, R ^a   Aranda, E ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Colorectal cancer; Cytotoxicity inhibition; ICAM1; S Icam1

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL AGGREGATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SERUM;

AGED; CELL AGGREGATION; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; NEOPLASM STAGING; TUMOR ESCAPE;

EID: 0032005571     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10033-8     Document Type: Article

References (32)

1. 1. Seth R, Raymond FD, Makgoba MW. Circulating ICAM-1 isoforms: diagnostic prospects for inflamatory and immune disorders. The Lancet 1991, 338, 83-84.
2. 2. Bajaj P, Lawry J, Shelton G, Rees RC. I1-6 and TNF synergistically block S-phase cell cycle and upregulate ICAM-1 expression on MCF-7 breast carcinoma cells. Cancer Lett 1993, 71(1), 143-149.
3. 3. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by GM-CSF and IL-4 and downregulated by TNF alfa. J Exp Med 1994, 179(4), 1109-1118.
4. 4. Abe Y, Watanabe Y, Kimura S. The role of TNF receptors in cell signaling and the significance of soluble form levels in the serum. Surg Today 1994, 24(3), 197-202.
5. 5. Lu Y, Ussery GD, Muncaster MM, Gallie BL, Blank G. Evidence for RB protein dependent and independent IFN-Gamma responses: RB coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells. Onogene 1994, 9(4), 1015-1019.
6. 6. Shen J, Devery JM, King NJ. Adherence status regulates the primary cellular activation responses to the flavivirus West Nile. Immunology 1995, 84(29), 254-264.
7. 7. Dean PA, Ramsey PS, Nelson H. Gamma-IFN enhances bifunctional antibody mediated tumor cells by lysis by increasing ICAM-1 dependent adhesion. Proc Am Assoc Cancer Res 1993, 43, 472-476.
8. 8. Azuma A, Yagita H, Matsuda H, Okumura K, Niitani H. Induction of ICAM-1 on SCLC cell lines by gamma-IFN enhances spontaneous and bispecific anti-CD3 antitumor directed LAK cell cytotoxicity. Cancer Res 1992, 52, 4890-4894.
9. 9. Melis M, Melodia A, D'Amico D, Gjomarkaj M, Spatafora M, Bonsignore G. Regulation of ICAM-1 expression on lung cancer cells by cytokines: effects on their adhesion to LAK cells and susceptibility to LAK cell citotoxicity. Lung Cancer 1994, 11 (Suppl), 24.
10. 10. Mizumo M, Yoshida J, Takaoka T, Sugita K. Reinforced citotoxicity of LAK cells toward glioma cells by transfection of the killer cells with the gamma interferon gene. Jpn J Cancer Res 1995, 86(1), 95-100.
11. 11. Schardt C, Heymanns J, Rotsch M, Havemann K. Differential expression of the ICAM-1 in lung cancer cell lines of various histological types. Eur J Cancer 1993, 29(16), 2250-2255.
12. 12. Pozo MA, Campanero MR, Pulido R, Melero I, Lopez-Botet M, Sanchez-Madrid F. Expression and function of ICAM-3 on human leucocytes. Possible participation in NK cell mediated tumoral lysis. Oncologia 1993, 16(7), 85-88.
13. 13. Tomita Y, Nishiyama T, Watanabe H, Fujiwara M, Sato S. Expression of ICAM-1 on renal cell cancer: possible significance in host immune responses. Int J Cancer 1990, 46, 1001-1006.
14. 14. Passlick B, Izbicki JR, Simmel S. Expression of histocompatibility class I and class II antigen and ICAM-1 on operable NSCLC: prognostic and prognostic significancy. Eur J Cancer 1994, 30(3), 376-381.
15. 15. Natali P, Nicotra MR, Cavalier R, et al. Differential expression of ICAM-1 in primary and metastatic melanoma lesion. Cancer Res 1990, 50, 1271-1278.
16. 16. Reitmuller G, Schlimockk G, Pantel K, et al. Cellular adhesion molecules in primary melanoma and characteristics of micrometastatic cells in various epithelial cancers. Int. Conference on Biol. Treatment of Melanoma and Other Cancers. Newcastle, 1992.
17. 17. Kelly CP, O'Keane JC, Orellana J, et al. Human colon cancer cells express ICAM-1 in vivo and support LFA-1 dependent lymphocyte adhesion in vitro. Am J Physiol 1992, 263, 864-870.
18. 18. Banks RE, Gearing A, Hemingway IC, Nordfolk DR, Perren TJ, Selby PJ. Circulating ICAM-1, E-selectin and VCAM-1 in human malignancies. Br J Cancer 1993, 68, 122-124.
19. 19. Becker JC, Dummer R, Hartmann AA, Burg G, Schmidt RE. Shedding of ICAM-1 from human melanoma cell lines induced by gamma-IFN and alfa-TNF. J Immunol 1991, 147, 4398-4401.
20. 20. Altomonte M, Colizzi F, Esposito G, Maio M. Circulating ICAM-1 is a marker of disease progression in cutaneous melanoma. N Engl J Med 1992, 327, 959-960.
21. 21. Harning R, Mainolfy E, Bystryng JC, Henn M, Merluzzi VJ, Rothlein R. Serum levels of circulating ICAM-1 in human malignant melanoma. Cancer Res 1991, 51, 5003-5005.
22. 22. Gruss HJ, Dolken G, Brach M, Mertelsmann R, Hermann F. Serum levels of ICAM-1 are increased in Hodgkin's disease. Leukemia 1993, 7, 1245-1249.
23. 23. Becker JC, Dummer R, Schwinn A, Hartmann AA, Burg G. Circulating ICAM-1 in melanoma patients: induction by IL-2 therapy. J Immunother 1992, 12, 147-150.
24. 24. Giavazzi R, Chirivi RG, Garofalo A. Soluble ICAM-1 is released by human melanoma cells and is associated with tumor growth in nude mice. Cancer Res 1992, 52, 2628-2630.
25. 25. Ramirez R, Solana R, Carracedo J, Alonso MC, Peña J. Mechanisms involved in NK resistance induced by gamma IFN. Cell Immunol 1992, 139, 248-256.
26. 26. Marubayashi M, Solana R, Ramirez R, Aranda E, Galan F, Peña J. Sera from patients with colon, breast and lung cancer induce resistance to lysis mediated by NK cytotoxic factors. Br J Cancer 1991, 63, 893-896.
27. 27. Reiter Z, Chen L, Revel M, Rubinstein M. IL-6 protects ductal breast carcinoma cells from MHC-unrestricted cell mediated cytotoxicity. Lymphokine Cytokine Res 1992, 11(3), 175-181.
28. 28. Becker JC, Termeer C, Schmidt RE, Brocker EB. Soluble ICAM-1 inhibits MHC-restricted specific T-cell/tumor interaction. J Immunol 1993, 151(12), 7224-7232.
29. 29. Dummer R, Nestle F, Schafer E, et al. Influence of soluble IL-2 receptor and soluble CD-8 proteins NK-cell activity and clinical course in cutaneous T-cell lymphoma patients. Arch Dermatol Res 1990, 8, 557-561.
30. 30. Rivoltini L, Cattoretti G, Arienti F, Mastroiani A, Parmiani G. CEA and NCA expressed by colon carcinoma cells affect their interaction with lysability by activated lymphocytes. Int J Biol Markers 1992, 7(39), 143-147.
31. 31. Koyama S. Immunosuppressive effect of shedding ICAM-1 antigen on cell mediated cytotoxicity against tumor cells. Jpn J Cancer Res 1994, 85(2), 131-134.
32. 32. Reilly PL, Woska JR, Jeanfavre DD, McNally E, Rothlein R, Bormann BJ. The native structure of ICAM-1 is a dimer: correlation with binding to LFA-1. J Immunol 1995, 155, 529-532.